Takeda Pharmaceutical (TKPHF) Capital Expenditures (2018 - 2026)

Takeda Pharmaceutical's Capital Expenditures history runs 9 years deep, the most recent figure standing at -$295.6 million for Q1 2026.

• In Q1 2026, Capital Expenditures rose 7.56% year-over-year to -$295.6 million; the TTM figure through Mar 2026 stood at -$1.2 billion (up 11.21% YoY), while the FY2026 annual figure was -$1.2 billion, up 11.3% from the prior year.
• Capital Expenditures was -$295.6 million for Q1 2026 at Takeda Pharmaceutical, down from -$270.5 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $2.1 billion in Q1 2024 to a low of -$369.0 million in Q2 2024.
• Historically, Capital Expenditures has averaged $91.8 million across 5 years, with a median of -$295.6 million in 2026.
• The sharpest annual moves came in 2022 and 2025: Capital Expenditures gained 24.09% in 2022, then slumped 115.47% in 2025.
• A 5-year view of Capital Expenditures shows it stood at -$236.9 million in 2022, then sank by 34.46% to -$318.5 million in 2023, then gained by 6.88% to -$296.6 million in 2024, then increased by 8.78% to -$270.5 million in 2025, then decreased by 9.28% to -$295.6 million in 2026.
• The last three Capital Expenditures figures came in at -$295.6 million (Q1 2026), -$270.5 million (Q4 2025), and -$272.1 million (Q3 2025), per Business Quant data.